Kindred Biosciences, Inc.: directors' dealings · United States · SEC (Form 4)

About Kindred Biosciences, Inc.

Kindred Biosciences, Inc. (ticker: KIN) was a U.S.-based animal health biotechnology company that was formerly listed on the NASDAQ in the United States. Founded in 2012 and headquartered in Burlingame, California, the company focused on developing veterinary therapeutics, with an emphasis on biologic medicines for companion animals such as dogs and cats. Its strategy centered on research and development, regulatory advancement, manufacturing preparation, and, for select assets, commercial partnering. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1561743/000156174314000010/kindredbio10-k.htm?utm_source=openai)) From an operating perspective, KindredBio positioned itself as an innovation-driven developer rather than a broad animal-health distributor. Public filings indicated that its portfolio included more than 20 product candidates at one point, predominantly biologics, and that it had also achieved at least two approved products prior to its acquisition. That mix gave the company a differentiated profile within veterinary medicine, where product development, clinical evidence, and regulatory execution are central to value creation. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1561743/000156174320000009/kindredbio201910-k.htm?utm_source=openai)) In competitive terms, KindredBio occupied a specialized niche at the intersection of biotechnology and animal health. Its key competitive advantage was the ability to target unmet veterinary needs with biologic assets that could command higher scientific and strategic value than conventional animal-health products. While it competed indirectly with much larger global animal-health companies, its focus on companion-animal therapeutics gave it a distinct, high-science positioning. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1561743/000156174321000060/k9-knightdefinitiveproxyst.htm?utm_source=openai)) The most important recent corporate development was its acquisition by Elanco Animal Health. Elanco announced the deal in June 2021 and completed it in August 2021, paying $9.25 per share for an aggregate cash consideration of about $444 million. Following closing, KindredBio’s common stock stopped trading on the NASDAQ, and the company ceased to exist as an independent publicly listed issuer. For investors reviewing SEC Form 4 insider transactions, that historical context is essential: KIN-related filings should be understood as legacy filings from a now-acquired company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1739104/000173910421000013/elan-20210630.htm?utm_source=openai)) Overall, Kindred Biosciences was a small-cap veterinary biotech founded in 2012 in the United States, listed on the NASDAQ, and built around a biologics pipeline for companion animals. Its analytical significance lies in its specialized R&D platform, its approved-product base, and its eventual acquisition, which validated the strategic value of its animal-health assets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1561743/000156174314000010/kindredbio10-k.htm?utm_source=openai))